Has Anyone Gotten Thyroid Cancer From Mounjaro? Honest Numbers, Honest Limits

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Topic: thyroid cancer surveillance for tirzepatide

Key Takeaways

• Yes, thyroid cancer has been reported in patients taking Mounjaro; FAERS and case series document individual cases
• Co-occurrence is not causation; individual cases cannot prove the medication caused the cancer
• Tirzepatide entered the U.S. market in May 2022, so the human evidence base is shorter than for semaglutide
• The SURPASS and SURMOUNT trial programs did not show statistically significant thyroid cancer increases vs comparators
• MTC and MEN-2 contraindications are absolute and must be observed; for everyone else, routine screening is not recommended and symptom-driven surveillance is the standard

Direct answer

Patients have been diagnosed with thyroid cancer while taking Mounjaro. The reports exist in FAERS and in case series. Whether the medication caused these cancers is unproven. Population-scale studies covering GLP-1 medications, including the 2024 Wang JAMA paper, have not shown a statistically significant overall increase in thyroid cancer. The tirzepatide-specific evidence is shorter and less mature than for semaglutide because the drug is newer, which makes long-latency findings less visible. The boxed warning and MTC/MEN-2 contraindications apply strictly. For patients without contraindications, current evidence does not justify avoiding Mounjaro purely for thyroid cancer concerns.

Table of contents

1. The shape of the question
2. What FAERS shows for tirzepatide specifically
3. SURPASS and SURMOUNT trial cancer data
4. The 2024 Wang JAMA paper and what it covered
5. Why tirzepatide data are shorter than semaglutide data
6. MTC vs other thyroid cancers in the warning structure
7. Litigation involving Mounjaro
8. Decision framework for current and prospective patients
9. The contrary view: long-latency uncertainty
10. FAQ
11. Sources

The shape of the question

"Has anyone gotten thyroid cancer from Mounjaro" carries the same dual-layer structure as the equivalent Ozempic question. The factual layer asks whether any patient has been diagnosed. The causal layer asks whether the medication caused the diagnosis. The honest answer to the first is yes; the honest answer to the second is that current evidence does not support a clear causal link in humans.

Tirzepatide's shorter market exposure changes the texture of the answer. Fewer total patient-years of exposure mean fewer accumulated reports, smaller statistical power, and less ability to detect long-latency findings. The reassuring data we do have are not yet conclusive about the longer horizon.

What FAERS shows for tirzepatide specifically

The FDA Adverse Event Reporting System contains thyroid cancer reports for tirzepatide accumulated since the drug's May 2022 approval. The volume is smaller than for semaglutide because tirzepatide has been on the market for a shorter period and prescription volume has only recently scaled.

FAERS data on tirzepatide and thyroid cancer:

• Reports exist and the count has grown as prescribing has expanded
• The reports include MTC and other thyroid cancer types (papillary, follicular, anaplastic)
• Reports are voluntarily submitted by clinicians, patients, and manufacturers
• Selection bias is real: cases in patients on a drug with a boxed warning are more likely to be reported than equivalent cases in patients on non-warning drugs
• The denominator (total tirzepatide-treated patients) cannot be reliably calculated from FAERS

The signal from FAERS for tirzepatide is currently consistent with the underlying baseline incidence of thyroid cancer in the treated population. That does not rule out a small effect; it simply means no large effect has emerged.

SURPASS and SURMOUNT trial cancer data

The pivotal trial programs for tirzepatide enrolled large cohorts with relatively short follow-up. The SURPASS trials (1 through 5 and beyond) supported the Mounjaro indication for type 2 diabetes. The SURMOUNT trials (1 through 4 and follow-on studies) supported the Zepbound indication for chronic weight management.

Cancer adverse events were captured systematically in these trials. Thyroid cancer cases were rare in absolute terms, consistent with rarity at baseline. The number of cases did not differ statistically from the comparator groups, which included placebo and other glucose-lowering medications depending on trial design.

Trial follow-up was generally 1-2 years for active treatment, with extension data in some studies. Cancer detection within this window is limited by latency. Thyroid cancers can develop over decades, so trial cohorts are not the right instrument for detecting very long-latency carcinogenesis. Post-marketing surveillance is the means by which that question gets answered, over time.

The 2024 Wang JAMA paper and what it covered

The 2024 Wang et al. study in JAMA examined GLP-1 receptor agonist use and thyroid cancer risk using U.S. claims data. The study population included patients on semaglutide, liraglutide, dulaglutide, and other GLP-1 medications. Tirzepatide was included where exposure was sufficient; the lower prescription volume in the early post-approval window limited the tirzepatide-specific power.

The headline finding was no statistically significant overall increase in thyroid cancer associated with GLP-1 use. The analysis was rigorous, with active-comparator design, new-user follow-up, and adjustment for multiple confounders. The authors noted the limitations: follow-up was relatively short and rare cancer subtypes were challenging to study with high power.

For tirzepatide specifically, the Wang paper added a data point consistent with the broader class finding rather than identifying anything unique. Tirzepatide-specific studies with larger samples and longer follow-up are in progress and will sharpen the picture over the coming years.

Why tirzepatide data are shorter than semaglutide data

Semaglutide was FDA-approved for type 2 diabetes in December 2017 as Ozempic. Wegovy followed in June 2021. Tirzepatide was approved as Mounjaro in May 2022 and as Zepbound in November 2023.

Practical implications:

• Semaglutide has roughly 4-5 more years of widespread U.S. exposure than tirzepatide
• Total person-years of tirzepatide exposure are still growing rapidly as prescribing expands
• Long-latency cancer signals require time to accumulate; current absence is not the same as final answer
• Pharmacovigilance over the next 5-10 years will be the period during which any tirzepatide-specific signal would likely emerge if one exists

This is the normal pattern for newer medications. The first 5 years of widespread use surface the more common and more rapid adverse events. The longer-latency questions answer themselves over a longer horizon. The honest framing is that tirzepatide's long-term cancer profile is still being characterized, and current data are reassuring but not yet definitive on the multi-decade question.

MTC vs other thyroid cancers in the warning structure

The boxed warning addresses medullary thyroid carcinoma (MTC) specifically because that is the cancer type observed in rodent tirzepatide studies. MTC arises from C-cells and is rare in humans, accounting for roughly 1-2% of thyroid cancers. Most U.S. thyroid cancer is papillary or follicular, arising from follicular cells, with a different biology and no current GLP-1 association.

The contraindications target the population most likely to be harmed if the rodent finding extended to humans: patients with personal or family history of MTC, and patients with MEN-2 syndrome who carry germline RET mutations predisposing to MTC. Excluding these patients reduces the most plausible scenario in which the rodent finding would matter.

For patients with other thyroid cancer history (papillary or follicular), the situation is more nuanced. There is no specific boxed warning for these cancers, but individual case discussion with the prescribing clinician and endocrinologist is appropriate.

Litigation involving Mounjaro

As of 2026 there is active U.S. litigation involving GLP-1 medications, including tirzepatide products, with claims related to thyroid cancer, pancreatic cancer, gastroparesis, and other outcomes. Some cases have been consolidated in multidistrict litigation; others are pending in state courts.

The existence of lawsuits is not evidence that the medication causes harm. It is evidence that legal claims are being filed and adjudicated. Outcomes will depend on legal standards (often a different threshold than scientific causation), expert witness testimony, and case-specific facts.

Patients evaluating these claims for personal decision-making should consider the published scientific evidence as the primary input. Lawsuits can sometimes track real problems (rofecoxib) and sometimes track patterns that do not survive scientific scrutiny. The current GLP-1 litigation has not yet produced rulings that resolve the underlying epidemiologic questions either way.

Decision framework for current and prospective patients

Do not use Mounjaro if:

• You have personal history of MTC
• You have first-degree family history of MTC
• You have MEN-2 syndrome
• You have known hypersensitivity to tirzepatide

Discuss with your prescriber and endocrinology if:

• You have papillary or follicular thyroid cancer history
• You have a thyroid mass currently under evaluation
• You have a family history of thyroid cancer of uncertain type

Continue or start standard therapy if:

• You meet FDA indications
• You have no contraindications
• You understand the precautionary basis of the boxed warning and the current limits of the evidence
• You commit to reporting new symptoms

If you develop concerning thyroid symptoms:

• Report promptly
• Expect evaluation with physical exam, possibly ultrasound and biopsy
• Continued therapy depends on findings and risk-benefit reassessment

The contrary view: long-latency uncertainty

The case for greater caution with tirzepatide than the current data alone suggest rests on the latency problem. Many cancers develop over decades. Tirzepatide has been in widespread U.S. use for roughly 2-3 years (Mounjaro) or 1-2 years (Zepbound). The total person-years of exposure are smaller than the equivalent number for semaglutide.

If tirzepatide does cause some excess risk that takes 5-10 years to emerge in pharmacovigilance, we are inside the window where it would not yet be visible. Reassuring current data does not exclude a future finding.

This does not justify avoiding tirzepatide for eligible patients. It justifies maintaining the contraindications, continuing surveillance, and revisiting the safety picture annually as more years of data accumulate. It also justifies appropriate epistemic humility in any claim about tirzepatide's long-term cancer profile.

Worth holding alongside: tirzepatide produces large weight loss that reduces the risk of multiple obesity-related cancers. The net cancer effect depends on the balance, and the balance is currently more likely to be favorable or neutral than harmful for the eligible obese population.

FAQ

Has anyone gotten thyroid cancer from Mounjaro?

Cases have been reported in FAERS and case series. Co-occurrence is not causation; population studies have not confirmed a measurable increase.

What FAERS data exist for Mounjaro and thyroid cancer?

FAERS contains thyroid cancer reports for tirzepatide accumulated since 2022. The total is smaller than for semaglutide because the exposure window is shorter.

How does the Mounjaro evidence compare to the Ozempic evidence?

The Mounjaro evidence base is younger and smaller. Semaglutide has more person-years of human exposure.

Did the SURPASS or SURMOUNT trials report thyroid cancer?

Thyroid cancer cases were reported at rates not statistically different from comparator groups.

What is medullary thyroid carcinoma and why does it matter for Mounjaro?

MTC arises from C-cells and is the cancer type observed in rodent tirzepatide studies. Patients with MTC or MEN-2 history are contraindicated.

Are there lawsuits about Mounjaro and thyroid cancer?

Yes, as of 2026. Lawsuits are not scientific evidence.

What thyroid symptoms should prompt evaluation while on Mounjaro?

New neck lumps, asymmetry, persistent hoarseness, swallowing difficulty, voice changes, or unexplained neck pain.

Should I switch from Mounjaro to a non-GLP-1 medication for cancer safety?

Not based on current evidence alone. Switching decisions should be made with your prescriber.

Does Zepbound carry the same thyroid cancer concerns?

Yes. Zepbound is tirzepatide for weight management; the molecule is the same as Mounjaro.

What if my family history of thyroid cancer is not MTC?

Most family thyroid cancer is papillary. The boxed warning specifically addresses MTC; papillary family history is a discussion point but not an absolute contraindication.

Should I get periodic calcitonin testing on Mounjaro?

Routine calcitonin testing is not recommended for asymptomatic patients. Symptom-driven evaluation is the standard approach.

Related guides

• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Cases and the Studies Actually Show
• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Evidence Actually Shows
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• Has Anyone Got Thyroid Cancer from Ozempic? What the Evidence Actually Shows
• Why Zepbound Kills Alcohol Cravings: Reward Circuits, GLP-1 Signaling, and Honest Limits of the Evidence
• TSH Levels Explained: What Your Thyroid Numbers Mean

Sources

1. FDA. Mounjaro Prescribing Information (Boxed Warning and Contraindications). 2024 update.
2. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Tirzepatide Reports. Accessed 2026.
3. Wang Y et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Thyroid Cancer. JAMA. 2024.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Garvey WT et al. Tirzepatide Once Weekly in People with Type 2 Diabetes and Obesity (SURMOUNT-2). The Lancet. 2023.
6. Rosenstock J et al. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). The Lancet. 2021.
7. American Thyroid Association Guidelines for Medullary Thyroid Carcinoma. 2015.
8. National Cancer Institute SEER Program. Thyroid Cancer Incidence and Survival Statistics. Updated 2025.
9. American Diabetes Association. Standards of Care in Diabetes 2025.
10. Endocrine Society. Clinical Practice Guideline on Pharmacotherapy for Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians and U.S. pharmacies. We do not provide direct oncology or endocrinology care. Information here is general and not a substitute for individualized clinical evaluation.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by state-licensed 503A pharmacies and carries the same boxed warning and contraindications as branded Mounjaro or Zepbound because the active molecule is the same.

Results Disclaimer. Case reports describe individual experiences that may not generalize. Population studies describe averages that may miss subgroup or long-latency effects. The tirzepatide evidence base continues to mature.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends has no affiliation with, endorsement from, or sponsorship by Eli Lilly, Novo Nordisk, FAERS, JAMA, or any party in current GLP-1 litigation.